Evidence map›Paper›PMID 41685961›Full record

ReviewThe Journal of infectious diseases2026

Immune Responses to Phage Therapy in Humans: A Review.

Kiran Bosco, Aleksandra Petrovic Fabijan, Jonathan Iredell, Krystyna Dabrowska, Ameneh Khatami

Abstract readReview
In one paragraph

Review in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Phage therapy againstFrontiers in microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kiran BoscoCentre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.ORCID 0009-0000-4087-2362
Aleksandra Petrovic FabijanCentre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0003-3172-2375
Jonathan IredellCentre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0003-2469-7060
Krystyna DabrowskaLaboratory of Phage Molecular Biology, Institute of Immunology and Experimental Therapy, Wrocław, Poland.
Ameneh KhatamiSydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-9114-6694

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review explores mammalian immune responses to phages with a particular emphasis on human immune responses to therapeutic phages and their potential implications for the outcomes of phage therapy. Despite the ubiquity of phages in the human microbiome, particularly in the gut (the phageome), research on immunological mechanisms governing immune responses to both endogenous and therapeutic phages are still in their infancy. We highlight key components of the immune system that contribute to clearance of phages in vivo and examine how various factors- including patient-specific variables, treatment regimens and phage characteristics can influence immune responses and, consequently, phage pharmacokinetics during therapy. A clearer understanding of human immune responses to phages is urgently needed to inform the development of more targeted and effective personalized phage therapies-an essential step in combating the escalating threat of antimicrobial resistance.

Indexed as

BacteriophagesPhage TherapyAnimalsHumansantiphage antibodiesimmune responsephage immunogenicityphage therapytherapeutic phage monitoring

Identifiers

PMID41685961
PMCPMC13175621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.